BioNTech SE said an experimental drug succeeded in a breast cancer study, the first dividend of the German Covid-19 vaccine maker’s collaboration with Chinese biotech Duality Biotherapeutics Inc.
The next-generation medicine beat Roche Holding AG’s older breast-cancer therapy Kadcyla in the study, with patients who got the new drug less likely to see their cancer get worse or to die, BioNTech said Friday. The results came at an interim analysis before the study had been scheduled to complete.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.